Used in cancer immunotherapy to enhance anti-tumor immune responses by blocking the TIM-3 receptor on immune cells. This inhibition prevents immune suppression in the tumor microenvironment, allowing T cells to remain active and attack cancer cells more effectively. Investigated in clinical trials for various solid tumors and hematologic malignancies, often in combination with other checkpoint inhibitors like anti-PD-1/PD-L1 antibodies. Shows potential in overcoming resistance to existing immunotherapies.